



3.5 mg/mL concentrate  
for solution for infusion

Symposium Chair:

**Alice Yu, USA**

*SIOP Congress, 2015*

*CITC Convention Square, Cape Town*

**Auditorium II, Friday 9 October 2015, 12:50-14:20**

Symposium title:

## Practical Considerations for a New Standard of Treatment in High-Risk Neuroblastoma Patients

### AGENDA

**12:50 High-risk neuroblastoma and today's immunotherapy landscape**

*Frank Berthold, Germany*

**13:05 The development of Unituxin™**

*Robert Grover, UK*

**13:20 Setting a new standard in high-risk neuroblastoma: Clinical overview and experience**

*Alice Yu, USA*

**13:35 Administering with confidence: Practical management to optimise treatment (before, during and after immunotherapy)**

*Erin Armideo-Bremhorst, USA*

**13:50 Case study examples: Unituxin immunotherapy in practice**

*Alice Yu, USA*

*Erin Armideo-Bremhorst, USA*

**14:05 Panel Q&A**

**Satellite symposium organised by:** United Therapeutics (not included in the main event CME/CPD credit offering)  
SIOP 2015 has provided space for this industry session. The programme was independently produced, not subject to review by SIOP, and is not part of the scientific/educational programme offered by SIOP 2015.

Date of preparation: August 2015 EU/UTX/AUG15/022a

© 2015 United Therapeutics Corporation. All rights reserved

